US3716555A - New 5-nitrofuryl derivatives - Google Patents

New 5-nitrofuryl derivatives Download PDF

Info

Publication number
US3716555A
US3716555A US00084512A US3716555DA US3716555A US 3716555 A US3716555 A US 3716555A US 00084512 A US00084512 A US 00084512A US 3716555D A US3716555D A US 3716555DA US 3716555 A US3716555 A US 3716555A
Authority
US
United States
Prior art keywords
pyrazole
furyl
cyano
carbon atoms
nitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00084512A
Inventor
G Howarth
J Gainer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Corp
Original Assignee
Ciba Geigy Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Corp filed Critical Ciba Geigy Corp
Application granted granted Critical
Publication of US3716555A publication Critical patent/US3716555A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • compositions containing these compounds relate to pharmaceutical and animal feedstuff compositions containing these compounds and to methods for the treatment of a mammal suffering from microbial infections, particularly of urinary tract infections, comprising administering to said mammal an effective amount of such compound.
  • the invention also provides methods for protecting organic material susceptible to microbial attack with an effective amount of a compound according to the invention.
  • the present invention relates to compounds of the formula I wherein R is alkyl having from one to five carbon atoms, carbalkoxy having from one to five carbon atoms in the alkyl moiety, or hydroxyalkyl having from two to five carbon atoms;
  • R is hydrogen, alkyl having from one to five carbon atoms which may be unsubstituted or substituted partially or completely by chloro or bromo; cycloalkyl having from five to seven carbon atoms in the carbocyclic ring, aralkyl having up to twelve carbon atoms, or alkenyl having from two to four carbon atoms; and
  • R is alkyl having from one to three carbon atoms.
  • alkyl groups having from one to five carbon atoms are methyl, ethyl, n-propyl, isopropyl, n-butyl, tertiarybutyl and n-pentyl groups. If R, is an alkyl group then it preferably contains from one to three carbon atoms. Cycloalkyl of from five to seven carbon atoms embraces cyclopentyl, cyclohexyl and cycloheptyl groups, whereby the cyclohexyl group is preferred.
  • aralkyl is meant for example the benzyl group and other groups consisting of an aryl and an alkyl moiety, such as phenylethyl, naphthylrnethyl and the like.
  • Alkenyl containing from two to four carbon atoms embraces the vinyl, allyl, Z-methallyl, but-2 -enyl and but-3-enyl group.
  • the removal of alkanol as the reaction proceeds may be done by chemical means, for example by conducting the reaction in the presence of a carboxylic acid anhydride, such as acetic anhydride, or by physical means, for example by distilling off the alkanol as formed. If the reactants are liquid, the reaction may be carried out in the absence of solvent; if both the reactants are solid, or if desired in any case, the reaction may be carried out in the presence of any anhydrous non-reactive solvent.
  • a carboxylic acid anhydride such as acetic anhydride
  • the starting compounds of formula II are prepared by reacting the corresponding nitrofuryl-nitrilimine which in one of its canonical forms may be represented by the formula III.
  • the nitrofurylmitrilimine of formula III may conveniently be generated, as required, during the course of the reaction with malononitn'le, by treating with a base the corresponding nitrofuryl-a-halo-hydrazone having the formula IV OzNl J-C-halogen 0 t NHR (IV)
  • the process may, if desired, be effected in the presence of a conventional base or other hydrogen halide acceptor.
  • the halogen present in the halohydrazone of formula IV is preferably chlorine or bromine.
  • the compounds of the invention have valuable antimicrobial properties, and in particular have antibacterial, antimycoplasmal, anthelminthic, antiprotozoal, coccidiostatic, trypanocidal and antimalarial activity of value in human or veterinary medicine.
  • the compounds are particularly valuable in the treatment of infections of the intestinal and urinary tracts.
  • mice The toxicity of the compounds of the invention as demonstrated for example in mice is of favorable low order.
  • the active compounds are administered in dosages depending on the kind of infection, the species and the age, weight and particular condition of the individual being treated. in general the daily dosage upon oral application will vary from about i to 100 mg/kg for mammals.
  • the compounds may also be used to protect a high molecular weight hydrophobic or other organic material susceptible to bacterial or other microbial deteroriation by contacting the organic material with, impregnating in or otherwise treating with, the compounds in amounts up to about 5 percent by weight.
  • the compounds also find application as growthpromoting additives to animal feedstuffs, to which they may be added in proportion of from 5 to 500 parts per million.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising an antimicrobially effective proportion of an active compound of the invention and a pharmacologically acceptable solid carrier or liquid diluent.
  • compositions according to the invention contain at least one active compound of the invention as active substance together with a conventional pharmaceutical carrier.
  • a conventional pharmaceutical carrier for external use, for example in disinfecting healthy skin, disinfecting wounds and in treating dermatoses and affections of the mucous membranes caused by bacteria, ointments, powders and tinctures are used in particular.
  • the ointment bases may be anhydrous, for instance they can consist of mixtures of wool fat and soft paraffin, or they can consist of aqueous emulsions in which the active substance is suspended.
  • Suitable carriers for powders are, for instance, ricc starch and other starches; the bulk weight of the carriers may be made lighter, if desired, for example by adding highly dispersed silicic acid, or may be made heavier by adding talcum.
  • the tinctures may contain at least one active ingredient in aqueous ethanol, in particular 45 percent to 75 percent ethanol, to which percent to percent of glycerol may be added, if desired. Solutions prepared from polyethylene glycol and other conventional solubility promoters, and also, optionally, from emulsifying agents, may be used with particular advantage in disinfecting healthy skin.
  • the content of active ingredient in pharmaceutical compositions for external application is preferably in the range of from 0.1 percent to 5 percent.
  • Gargles or concentrates for their preparation, and tablets for slow dissolution in the mouth are suitable for the disinfection of the mouth and throat.
  • the former are preferably prepared form alcoholic solutions containing 1 percent to 5 percent of active substance to which glycerol or flavorings may be added.
  • Lozenges that is solid dosage units, preferably have a relatively high content of sugar or similar substances and a relatively low content of active substance, for instance 0.2 percent to 20 percent by weight, as well as the usual conventional additives such as binding agents and flavorings.
  • Solid dosage units in particular tablets, dragees (sugar coated tablets) and capsules, are convenient for use in intestinal disinfection and for the :oral treatment of urinary tract infections. These units preferably contain from 10 percent to percent of the active compound to enable the administration of daily doses of from 0.1 to 2.5 grams to adults, or of suitable reduced doses to children to be made. Tablets and dragee cores are produced by combining the active compounds with solid, pulverulent carriers such as lactose, saccharose, sorbitol, maize starch, potato starch or amylopectin, cellulose derivatives or gelatines, preferably with the addition of lubricants such as magnesium or calcium stearate or polyethylene glycols of suitable molecular weight.
  • solid, pulverulent carriers such as lactose, saccharose, sorbitol, maize starch, potato starch or amylopectin, cellulose derivatives or gelatines, preferably with the addition of lubricants such as magnesium or calcium ste
  • Dragee cores may then be coated, for example with concentrated sugar solutions which can also contain gum arabic, talcum and/or titanium dioxide, or they may be coated with a lacquer dissolved in volatile organic solvents or mixture of solvents.
  • Dyestuffs can be added to these coatings, for instance to differentiate between varying dosages.
  • Soft gelatine capsules and other closed capsules consist, for example, of a mixture of gelatines and glycerol and may contain, for example, mixtures of the active compound with polyethylene glycol.
  • Hard gelatine capsules contain, for example, granulates of an active substance with solid pulverulent carriers, for instance lactose, saccharose, sorbitol, mannitol, starches (such as potato starch, maize starch or amylopectin), cellulose derivatives of gelatins, and magnesium stearate or stearic acid.
  • solid pulverulent carriers for instance lactose, saccharose, sorbitol, mannitol, starches (such as potato starch, maize starch or amylopectin), cellulose derivatives of gelatins, and magnesium stearate or stearic acid.
  • the active compounds can be present as solo active ingredients or they can also be combined with other known pharmacologically active, and especially antibacterial and/or antimycotically or other anti-microbially active substances, for example to broaden the range of application. They can be combined for example, with 5,7-dichloro-2-methyl-8- quinolinol or other derivatives of 8-quinolinol, with sulfamerazine or sulfafurazole or other derivatives of sulfanilamide, with chloramphenicol or tetracycline or other antibiotics, with '3,4,5-tribromosalicylanilide or other halogenated salicylanilides, with halogenated carbanilides, with halogenated benzoxazoles or benzoxazolones, with polychloro-hydroxy-diphenylmethanes, with halogen-dihydroxy-diphenyl sulphides, with 4,4 -dichloro-Z-hydroxydiphenyl
  • the invention also provides a method of protecting an organic material susceptible to bacterial or other microbial attack which comprises treating the material with an active compound of the invention.
  • the organic material may be, for instance, a natural or synthetic polymeric material, a proteinaceous or carbohydrate substance, or a natural or synthetic fiber or textile material formed therefrom.
  • the invention also provides an animal feedstuff composition comprising an active compound of the invention in an amount sufficient to promote the growth of the animal fed with the composition.
  • EXAMPLE 1 1 Milliliter of acetic anhydride and 12 milliliters of triethyl orthoformate were added to 1.0 gram of 5- amino-4cyano- 1 -methyl-3 5-nitro-2-furyl )-pyrazole, and the mixture was refluxed for 5 hours. After this period of heating, the excess ethyl orthoformate and acetic anhydride were removed by distillation under reduced pressure. The crude residue was recrystallized and the product was 4-cyano-5-ethoxymethyleneamino-l -methyl-3-( 5-nitro-2-furyl pyrazole.
  • EXAMPLE 2 A mixture of 5 grams of 5-amino-4-cyano-l-(2- hydroxyethyl)-3-(5-nitro-2-furyl)-pyrazole, 70 milliliters of triethyl orthoformate and 5 milliliters of acetic anhydride was heated under reflux for 4 hours and cooled. The crystalline solid was collected, washed with ether and dried. Recrystallization from ethyl acetate gave 4-cyano-5-ethoxymethyleneamino-l-(2- hydroxyethyl)-3-(5-nitro-2-fury1)-pyrazole, having melting point 1 16C.
  • the product was 4-cyano-5-(l-ethoxyethylideneamino)-l-methy1-3-(5-nitro-2-furyl)-pyrazo1e, having melting point 160C.
  • the product was 4-cyano-5-( l-ethoxypropylideneamino)-l-methy1-3-(5-nitro-2-furyl)-pyrazole, having melting point 161C.
  • EXAMPLE 5 PREPARATION OF TABLETS 100 g of 4-cyano-S-ethoxymethyleneamino-1- methyl-3-(5-nitro-2-furyl)- pyrazole are mixed with 60.0 g of maize starch and 35.0 g of lactose, the mixture is moistened with a solution of 5.0 g of gelatin and 3.0 g of glycerol in 70.0 g of water and granulated through a sieve. The granulate is mixed with a mixture of 15.0 g of talcum, 10.0 g of maize starch and 2.0 g of magnesium stearate. The resulting mixture is pressed into 1,000 tablets, each containing 100 mg of active substance. 1f desired, the tablets can be grooved for better adaption of the dosage.
  • Composition 1 is granulated in the heat with composition Il through a sieve of 1.2 mm mesh diameter. The dried granulate is mixed with composition 11] and the resulting mixture is pressed into 1,000 dragee cores. These are then coated with composition 1V and dried. The dragees obtained weight 255.0 mg and contain 100 mg of active substance.
  • the p-hydroxybenzoic acid esters, the citric acid and the sodium cyclamate are dissolved in the given amount of boiling distilled water; the glycerol is then added to this solution (11).
  • the sodium carboxymethyl cellulose and the sugar are thoroughly mixed (lll).
  • composition 111 is then added at C to Solution 11 under stirring until complete dissolution of 111.
  • the viscous, slightly turbid liquid is cooled to room temperature, filtered, if necessary, and mixed with composition I. Water is added to the resulting mixture up to the prescribed weight of 1,155.0 g and the syrup obtained is homogenized.
  • R is hydrogen,a1ky1 having from one to five carbon atoms which may be unsubstituted or substituted partially or completely by chloro or bromo;
  • cycloalkyl having from five to seven carbon atoms in the carbocyclic ring, benzyl, phenylethyl, naphthylmethyl, or alkenyl having from two to four carbon atoms;
  • R is alkyl having from one to three carbon atoms.
  • a compound according to claim 1 which is 4- cyano-S -ethoxymethyleneamino-1-methyl-3-(5-nitro-2 -furyl)-pyrazole.
  • a compound according to claim 1 which is 4- cyano-S-ethoxymethyleneaminol Z-hydroxyethyl )-3- (S-nitro-2-furyl)-pyrazole.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Earth Drilling (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of the class of 4-cyano-5-alkoxymethylenamino-3-(5nitro-2-furyl)-pyrazole have antimicrobial properties and are active ingredients in pharmaceutical compositions and animal feedstuff compositions; an illustrative example is 4-cyano-5ethoxymethylenamino-1-methyl-3-(5-nitro-2-furyl)-pyrazole.

Description

United States Patent Howarth et al.
[ 51 Feb. 13, 1973 S-NITROFURYL DERIVATIVES Inventors: Graham Arton Howarth, Wilmslow; James Gainer, Tyldesley, both of England Assignee: Ciba-Geigy Corporation, Ardsley,
Filed: Oct. 27, 1970 Appl. No.: 84,512
Foreign Application Priority Data Sept. 9, 1970 Great Britain ..43,056/70 US. Cl ..260/3l0 R, 260/45.8 NZ, 260/347.7,
424/273, 99/2 N Int. Cl. ..C07d 49/18 Field of Search ..260/3 10 [56] References Cited UNITED STATES PATENTS 3,414,580 l2/l968 Hohn ..260/310 Primary Examiner-Harry l. Moatz Attorney-Karl F. Jorda and Bruce M. Collins ABSTRACT 5 Claims, No Drawings DETAILED DESCRIPTION The present invention relates to nitrofuryl derivatives, in particular, to derivatives of 3-(5-nitro-2-furyl)- pyrazole which compounds have antimicrobial properties. It further relates to pharmaceutical and animal feedstuff compositions containing these compounds and to methods for the treatment of a mammal suffering from microbial infections, particularly of urinary tract infections, comprising administering to said mammal an effective amount of such compound. The invention also provides methods for protecting organic material susceptible to microbial attack with an effective amount of a compound according to the invention.
More particularly, the present invention relates to compounds of the formula I wherein R is alkyl having from one to five carbon atoms, carbalkoxy having from one to five carbon atoms in the alkyl moiety, or hydroxyalkyl having from two to five carbon atoms;
R, is hydrogen, alkyl having from one to five carbon atoms which may be unsubstituted or substituted partially or completely by chloro or bromo; cycloalkyl having from five to seven carbon atoms in the carbocyclic ring, aralkyl having up to twelve carbon atoms, or alkenyl having from two to four carbon atoms; and
R is alkyl having from one to three carbon atoms.
Examples of alkyl groups having from one to five carbon atoms are methyl, ethyl, n-propyl, isopropyl, n-butyl, tertiarybutyl and n-pentyl groups. If R, is an alkyl group then it preferably contains from one to three carbon atoms. Cycloalkyl of from five to seven carbon atoms embraces cyclopentyl, cyclohexyl and cycloheptyl groups, whereby the cyclohexyl group is preferred. By the term aralkyl is meant for example the benzyl group and other groups consisting of an aryl and an alkyl moiety, such as phenylethyl, naphthylrnethyl and the like. Alkenyl containing from two to four carbon atoms embraces the vinyl, allyl, Z-methallyl, but-2 -enyl and but-3-enyl group.
Compounds of formula I are produced by treating a compound of the formula II wherein R is as defined in formula I, with a compound of the formula wherein R and R are as defined in formula I, and removing the alkanol produced during the reaction by chemical or physical means as the reaction proceeds. The reaction is advantageously carried out at the reflux temperature of the reaction mixture.
The removal of alkanol as the reaction proceeds may be done by chemical means, for example by conducting the reaction in the presence of a carboxylic acid anhydride, such as acetic anhydride, or by physical means, for example by distilling off the alkanol as formed. If the reactants are liquid, the reaction may be carried out in the absence of solvent; if both the reactants are solid, or if desired in any case, the reaction may be carried out in the presence of any anhydrous non-reactive solvent.
The starting compounds of formula II are prepared by reacting the corresponding nitrofuryl-nitrilimine which in one of its canonical forms may be represented by the formula III.
(III) with malononitrile, where R has its previous significance.
The nitrofurylmitrilimine of formula III may conveniently be generated, as required, during the course of the reaction with malononitn'le, by treating with a base the corresponding nitrofuryl-a-halo-hydrazone having the formula IV OzNl J-C-halogen 0 t NHR (IV) The process may, if desired, be effected in the presence of a conventional base or other hydrogen halide acceptor. The halogen present in the halohydrazone of formula IV is preferably chlorine or bromine.
The compounds of the invention have valuable antimicrobial properties, and in particular have antibacterial, antimycoplasmal, anthelminthic, antiprotozoal, coccidiostatic, trypanocidal and antimalarial activity of value in human or veterinary medicine. The compounds are particularly valuable in the treatment of infections of the intestinal and urinary tracts.
Their antimicrobial activity is demonstrated in a number of conventional pharmacological tests. Thus it is shown that, for example, 4-cyano-5-ethoxymethyleneamino-l methyl-3-(S-nitro-Z-furyl)- pyrazole has in vitro an excellent growth inhibiting effeet against staphylococcus aureus, Escherichia coli, Klebsiella pneumonia, Salmonella typhi and others if added in amounts of about 1 to about 10 'y/ml to the bacterial culture.
The toxicity of the compounds of the invention as demonstrated for example in mice is of favorable low order.
For their intended internal use, for example for the treatment of intestinal and urinary tract infections, the active compounds are administered in dosages depending on the kind of infection, the species and the age, weight and particular condition of the individual being treated. in general the daily dosage upon oral application will vary from about i to 100 mg/kg for mammals. The compounds may also be used to protect a high molecular weight hydrophobic or other organic material susceptible to bacterial or other microbial deteroriation by contacting the organic material with, impregnating in or otherwise treating with, the compounds in amounts up to about 5 percent by weight. The compounds also find application as growthpromoting additives to animal feedstuffs, to which they may be added in proportion of from 5 to 500 parts per million.
Accordingly, the invention also provides a pharmaceutical composition comprising an antimicrobially effective proportion of an active compound of the invention and a pharmacologically acceptable solid carrier or liquid diluent.
The pharmaceutical compositions according to the invention contain at least one active compound of the invention as active substance together with a conventional pharmaceutical carrier. The type of carrier actually used depends to a great extent on the intended application; for external use, for example in disinfecting healthy skin, disinfecting wounds and in treating dermatoses and affections of the mucous membranes caused by bacteria, ointments, powders and tinctures are used in particular. The ointment bases may be anhydrous, for instance they can consist of mixtures of wool fat and soft paraffin, or they can consist of aqueous emulsions in which the active substance is suspended. Suitable carriers for powders are, for instance, ricc starch and other starches; the bulk weight of the carriers may be made lighter, if desired, for example by adding highly dispersed silicic acid, or may be made heavier by adding talcum. The tinctures may contain at least one active ingredient in aqueous ethanol, in particular 45 percent to 75 percent ethanol, to which percent to percent of glycerol may be added, if desired. Solutions prepared from polyethylene glycol and other conventional solubility promoters, and also, optionally, from emulsifying agents, may be used with particular advantage in disinfecting healthy skin. The content of active ingredient in pharmaceutical compositions for external application is preferably in the range of from 0.1 percent to 5 percent.
Gargles or concentrates for their preparation, and tablets for slow dissolution in the mouth, are suitable for the disinfection of the mouth and throat. The former are preferably prepared form alcoholic solutions containing 1 percent to 5 percent of active substance to which glycerol or flavorings may be added. Lozenges, that is solid dosage units, preferably have a relatively high content of sugar or similar substances and a relatively low content of active substance, for instance 0.2 percent to 20 percent by weight, as well as the usual conventional additives such as binding agents and flavorings.
Solid dosage units, in particular tablets, dragees (sugar coated tablets) and capsules, are convenient for use in intestinal disinfection and for the :oral treatment of urinary tract infections. These units preferably contain from 10 percent to percent of the active compound to enable the administration of daily doses of from 0.1 to 2.5 grams to adults, or of suitable reduced doses to children to be made. Tablets and dragee cores are produced by combining the active compounds with solid, pulverulent carriers such as lactose, saccharose, sorbitol, maize starch, potato starch or amylopectin, cellulose derivatives or gelatines, preferably with the addition of lubricants such as magnesium or calcium stearate or polyethylene glycols of suitable molecular weight. Dragee cores may then be coated, for example with concentrated sugar solutions which can also contain gum arabic, talcum and/or titanium dioxide, or they may be coated with a lacquer dissolved in volatile organic solvents or mixture of solvents. Dyestuffs can be added to these coatings, for instance to differentiate between varying dosages. Soft gelatine capsules and other closed capsules consist, for example, of a mixture of gelatines and glycerol and may contain, for example, mixtures of the active compound with polyethylene glycol. Hard gelatine capsules contain, for example, granulates of an active substance with solid pulverulent carriers, for instance lactose, saccharose, sorbitol, mannitol, starches (such as potato starch, maize starch or amylopectin), cellulose derivatives of gelatins, and magnesium stearate or stearic acid.
In all forms for administration the active compounds can be present as solo active ingredients or they can also be combined with other known pharmacologically active, and especially antibacterial and/or antimycotically or other anti-microbially active substances, for example to broaden the range of application. They can be combined for example, with 5,7-dichloro-2-methyl-8- quinolinol or other derivatives of 8-quinolinol, with sulfamerazine or sulfafurazole or other derivatives of sulfanilamide, with chloramphenicol or tetracycline or other antibiotics, with '3,4,5-tribromosalicylanilide or other halogenated salicylanilides, with halogenated carbanilides, with halogenated benzoxazoles or benzoxazolones, with polychloro-hydroxy-diphenylmethanes, with halogen-dihydroxy-diphenyl sulphides, with 4,4 -dichloro-Z-hydroxydiphenylether or 2',4,4'- trichloro-Z-hydroxydiphenylether or other polyhalogenhydroxydiphenylethers, or with bactericidal quaternary compounds or with certain dithiocarbamic acid derivatives such as tetramethylthiuram disulphide. Also, carriers which themselves have favorable pharmacological properties may be used, for instance sulphur as a powder base or zine stearate as a component of ointment bases.
i The invention also provides a method of protecting an organic material susceptible to bacterial or other microbial attack which comprises treating the material with an active compound of the invention. The organic material may be, for instance, a natural or synthetic polymeric material, a proteinaceous or carbohydrate substance, or a natural or synthetic fiber or textile material formed therefrom.
The invention also provides an animal feedstuff composition comprising an active compound of the invention in an amount sufficient to promote the growth of the animal fed with the composition.
The following examples will serve to further illustrate the nature of the present invention, however, they should not be construed as a limitation on the scope thereof.
EXAMPLE 1 1 Milliliter of acetic anhydride and 12 milliliters of triethyl orthoformate were added to 1.0 gram of 5- amino-4cyano- 1 -methyl-3 5-nitro-2-furyl )-pyrazole, and the mixture was refluxed for 5 hours. After this period of heating, the excess ethyl orthoformate and acetic anhydride were removed by distillation under reduced pressure. The crude residue was recrystallized and the product was 4-cyano-5-ethoxymethyleneamino-l -methyl-3-( 5-nitro-2-furyl pyrazole.
EXAMPLE 2 A mixture of 5 grams of 5-amino-4-cyano-l-(2- hydroxyethyl)-3-(5-nitro-2-furyl)-pyrazole, 70 milliliters of triethyl orthoformate and 5 milliliters of acetic anhydride was heated under reflux for 4 hours and cooled. The crystalline solid was collected, washed with ether and dried. Recrystallization from ethyl acetate gave 4-cyano-5-ethoxymethyleneamino-l-(2- hydroxyethyl)-3-(5-nitro-2-fury1)-pyrazole, having melting point 1 16C.
EXAMPLE 3 The procedure described in Example 2 was carried out using 5-amino-4-cyano-l-methyl-3-(5-nitro-2-furyl)-pyrazole and triethyl orthoacetate as starting materials the reaction conditions being the same.
The product was 4-cyano-5-(l-ethoxyethylideneamino)-l-methy1-3-(5-nitro-2-furyl)-pyrazo1e, having melting point 160C.
EXAMPLE 4 The procedure described in Example 2 was carried out using 5-amino-4-cyano-l-methyl-3-(5-nitro-2-furyl)-pyrazole and triethyl orthopropionate as starting material, the reaction conditions being the same.
The product was 4-cyano-5-( l-ethoxypropylideneamino)-l-methy1-3-(5-nitro-2-furyl)-pyrazole, having melting point 161C.
EXAMPLE 5 PREPARATION OF TABLETS 100 g of 4-cyano-S-ethoxymethyleneamino-1- methyl-3-(5-nitro-2-furyl)- pyrazole are mixed with 60.0 g of maize starch and 35.0 g of lactose, the mixture is moistened with a solution of 5.0 g of gelatin and 3.0 g of glycerol in 70.0 g of water and granulated through a sieve. The granulate is mixed with a mixture of 15.0 g of talcum, 10.0 g of maize starch and 2.0 g of magnesium stearate. The resulting mixture is pressed into 1,000 tablets, each containing 100 mg of active substance. 1f desired, the tablets can be grooved for better adaption of the dosage.
EXAMPLE 6 Preparation of Dragees Composition 1 4-Cyano-S-ethoxymethylenenamino- 1.
for 1,000 dragees Magnesium stearate T al- 0t W White dragee coating Shellac Su ar 5 T cum 3 Gum arabic Colloidal silicon dioxide Titanium dioxide one:
Composition 1 is granulated in the heat with composition Il through a sieve of 1.2 mm mesh diameter. The dried granulate is mixed with composition 11] and the resulting mixture is pressed into 1,000 dragee cores. These are then coated with composition 1V and dried. The dragees obtained weight 255.0 mg and contain 100 mg of active substance.
EXAMPLE 7 Preparation of a Syrup The active substance and the colloidal silicon dioxide are passed through a sieve of 1.2 mm mesh diameter (1).
The p-hydroxybenzoic acid esters, the citric acid and the sodium cyclamate are dissolved in the given amount of boiling distilled water; the glycerol is then added to this solution (11). The sodium carboxymethyl cellulose and the sugar are thoroughly mixed (lll).
Composition 111 is then added at C to Solution 11 under stirring until complete dissolution of 111. The viscous, slightly turbid liquid is cooled to room temperature, filtered, if necessary, and mixed with composition I. Water is added to the resulting mixture up to the prescribed weight of 1,155.0 g and the syrup obtained is homogenized.
What is claimed is:
l. A compound of the formula 1 OzNI 0N wherein R, is alkyl having from one to five carbon atoms, carbalkoxy having from one to five carbon atoms in the alkyl moiety or hydroxyalkyl having from two to five carbon atoms,
R is hydrogen,a1ky1 having from one to five carbon atoms which may be unsubstituted or substituted partially or completely by chloro or bromo;
cycloalkyl having from five to seven carbon atoms in the carbocyclic ring, benzyl, phenylethyl, naphthylmethyl, or alkenyl having from two to four carbon atoms; and
R is alkyl having from one to three carbon atoms.
2. A compound according to claim 1 which is 4- cyano-S -ethoxymethyleneamino-1-methyl-3-(5-nitro-2 -furyl)-pyrazole.
3. A compound according to claim 1 which is 4- cyano-S-ethoxymethyleneaminol Z-hydroxyethyl )-3- (S-nitro-2-furyl)-pyrazole.
4. A compound according to claim 1 which is 4-

Claims (4)

1. A compound of the formula I
2. A compound according to claim 1 which is 4-cyano-5-ethoxymethyleneamino-1-methyl-3-(5-nitro-2-furyl)-pyrazole.
3. A compound according to claim 1 which is 4-cyano-5-ethoxymethyleneamino-1-(2-hydroxyethyl)-3-(5-nitro-2-furyl) -pyrazole.
4. A compound according to claim 1 which is 4-cyano-5-(1-ethoxyethyleneamino)-1-methyl-3-(5-nitro-2-furyl)-pyrazole.
US00084512A 1969-10-28 1970-10-27 New 5-nitrofuryl derivatives Expired - Lifetime US3716555A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB5266369 1969-10-28
GB4305470 1970-09-09
GB4305670 1970-09-09
GB4305570 1970-09-09

Publications (1)

Publication Number Publication Date
US3716555A true US3716555A (en) 1973-02-13

Family

ID=27448964

Family Applications (2)

Application Number Title Priority Date Filing Date
US00084512A Expired - Lifetime US3716555A (en) 1969-10-28 1970-10-27 New 5-nitrofuryl derivatives
US00084531A Expired - Lifetime US3755324A (en) 1969-10-28 1970-10-27 3-(5-nitro-2-furyl)-1h-pyrazolo{8 3,4{9 pyrimidins-4(5h)-ones

Family Applications After (1)

Application Number Title Priority Date Filing Date
US00084531A Expired - Lifetime US3755324A (en) 1969-10-28 1970-10-27 3-(5-nitro-2-furyl)-1h-pyrazolo{8 3,4{9 pyrimidins-4(5h)-ones

Country Status (17)

Country Link
US (2) US3716555A (en)
AT (7) AT304519B (en)
BE (1) BE758050A (en)
BG (1) BG17005A3 (en)
CH (5) CH572053A5 (en)
DE (2) DE2052719A1 (en)
DK (1) DK130589B (en)
FR (1) FR2070170B1 (en)
GB (1) GB1326360A (en)
HK (1) HK52076A (en)
IE (1) IE34623B1 (en)
IL (1) IL35542A (en)
KE (1) KE2638A (en)
NL (1) NL7015412A (en)
NO (1) NO130007B (en)
RO (1) RO56795A (en)
SE (2) SE383747B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980794A (en) * 1974-05-13 1976-09-14 Eli Lilly And Company Method for promoting growth of poultry with 3-(5-nitro-2-imidazolyl)pyrazoles
US4093812A (en) * 1975-03-25 1978-06-06 Byk Gulden Lomberg Chemische Fabrik Gmbh (Nitrofuryl)pyrazoles, their synthesis and use, and compositions containing them
US5977118A (en) * 1995-03-10 1999-11-02 Sanofi 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones and compositions and methods of use thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888887A (en) * 1972-01-14 1975-06-10 American Home Prod Derivatives of 3-amino-2-halo-2-cyclohexen-1-one
AR204665A1 (en) * 1974-05-13 1976-02-20 Lilly Co Eli PROCEDURE FOR PREPARING 3- (5-NITROIMIDAZOL-2-IL) PYRAZOLO (3,4D) PYRIMIDINE COMPOUNDS
US4044130A (en) * 1974-07-03 1977-08-23 Ciba-Geigy Corporation Compositions for the control of microorganisms
DE2747531A1 (en) * 1977-10-22 1979-04-26 Basf Ag SUBSTITUTED 3-AMINOPYRAZOLE
US4282361A (en) * 1978-03-16 1981-08-04 Massachusetts Institute Of Technology Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines
MXPA06009462A (en) 2004-02-27 2007-03-15 Hoffmann La Roche Heteroaryl-fused pyrazolo derivatives.
CA2557575A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
KR20060114022A (en) 2004-02-27 2006-11-03 에프. 호프만-라 로슈 아게 Indazole derivatives and pharmaceutical compositions containing them
BRPI0615442A2 (en) 2005-08-25 2011-05-17 Hoffmann La Roche p38 map kinase inhibitors and methods for using them

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3414580A (en) * 1963-07-24 1968-12-03 Heyden Chem Fab Method for the production of substituted 5-aminopyrazoles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4032E (en) * 1902-10-22 1905-05-03 Francois Louis Dit Amedee Gira Device for automatic control of generator draft registers, which can also ensure smoke
CH398626A (en) * 1960-05-11 1966-03-15 Ciba Geigy Process for the preparation of new pyrazolopyrimidines
AT229863B (en) * 1961-10-11 1963-10-25 Norwich Pharma Co Process for the preparation of the new 2- (5-nitro-2-furyl) imidazo- [1,2-a] pyridine or pyrimidine
US3335141A (en) * 1964-08-17 1967-08-08 Norwich Pharma Co 4-substituted-1-alkyl-6-(5-nitro-2-furyl)-1h-pyrazolo[3, 4-d]pyrimidines
FR206F (en) * 1965-07-20

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3414580A (en) * 1963-07-24 1968-12-03 Heyden Chem Fab Method for the production of substituted 5-aminopyrazoles

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980794A (en) * 1974-05-13 1976-09-14 Eli Lilly And Company Method for promoting growth of poultry with 3-(5-nitro-2-imidazolyl)pyrazoles
US4093812A (en) * 1975-03-25 1978-06-06 Byk Gulden Lomberg Chemische Fabrik Gmbh (Nitrofuryl)pyrazoles, their synthesis and use, and compositions containing them
US5977118A (en) * 1995-03-10 1999-11-02 Sanofi 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones and compositions and methods of use thereof

Also Published As

Publication number Publication date
NO130007B (en) 1974-06-24
DK130589C (en) 1975-08-18
IE34623B1 (en) 1975-06-25
FR2070170B1 (en) 1974-02-22
CH549597A (en) 1974-05-31
CH549599A (en) 1974-05-31
RO56795A (en) 1974-08-01
CH549598A (en) 1974-05-31
AT303715B (en) 1972-12-11
IL35542A0 (en) 1971-04-28
AT299179B (en) 1972-06-12
DE2064874A1 (en) 1972-06-29
IE34623L (en) 1971-04-28
HK52076A (en) 1976-08-27
US3755324A (en) 1973-08-28
BG17005A3 (en) 1973-04-25
AT304519B (en) 1973-01-10
AT304517B (en) 1973-01-10
DE2052719A1 (en) 1971-09-16
SE402591B (en) 1978-07-10
DK130589B (en) 1975-03-10
BE758050A (en) 1971-04-27
CH572053A5 (en) 1976-01-30
AT304518B (en) 1973-01-10
GB1326360A (en) 1973-08-08
AT305994B (en) 1973-03-26
FR2070170A1 (en) 1971-09-10
NL7015412A (en) 1971-05-03
KE2638A (en) 1976-06-11
CH548412A (en) 1974-04-30
AT303714B (en) 1972-12-11
IL35542A (en) 1975-04-25
SE383747B (en) 1976-03-29

Similar Documents

Publication Publication Date Title
JPS62161728A (en) Antibacterial
US3716555A (en) New 5-nitrofuryl derivatives
US3679698A (en) 2-nitroimidazoles
US3769295A (en) Nitrofuryl derivatives of 5-substituted isoxazolines
US3228833A (en) Anticoccidial compositions and methods of using same
US4066776A (en) Anti-bacterial compositions containing certain 3-nitropyrazoles
US3948913A (en) New 5-nitrofuryl derivatives
US4044130A (en) Compositions for the control of microorganisms
US2920074A (en) 1-(5-nitrofurfurylideneamino)-2-imidazolidinethione
US3821382A (en) 5-nitrofuryl derivatives as antibacterial agents
US3682956A (en) Substituted 3-(5-nitro-2-furyl)-pyrazoles
US2762742A (en) 1-(4-nitro phenyl)-3-(2-pyrimidyl) urea compound for the treatment of coccidiosis and method of preparing the same
US3026332A (en) Nitrofurfurylidene hydroxy acid hydrazides
US3632577A (en) 5-nitrofuryl derivatives
US4328235A (en) Suppressing pain with benzothiazol-2(3H)-ones
US3906101A (en) Pharmaceutical compositions containing substituted 5-nitrofurfurylideneamino-oxazolidinones
US3835165A (en) Nitrofuryl-alpha-halo-hydrazones
US2847416A (en) Nu-[1-(5-nitro-2-furyl) ethylidene]-3-amino-2-oxazolidone
US3415838A (en) Nitrogen-containing derivatives of 2,5-dichloro-3-nitrobenzoic acid
US3598812A (en) 5-nitrofuryl derivatives
US3682953A (en) Substituted 5-nitrofuryl-pyrazoles
US3793316A (en) 5-nitrofuryl derivatives
US3686170A (en) Novel substituted t-nitrofurfurylideneamino-oxazolidinones
US3156699A (en) Nu-(5-nitro-thiazolyl-2) 2, 4-dinitropyrrole-1-acetamide
US3562286A (en) Nitrofuryl isoxazole derivatives